---
schema_version: "secwatch.filing_event.v1"
accession: "0001835268-25-000029"
form_type: "8-K"
ticker: "CNTB"
cik: "0001835268"
company_name: "Connect Biopharma Holdings Ltd"
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T09:57:57.733508+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Connect Biopharma starts Phase 2 COPD study of rademikibart, topline data expected 1H 2026

## Summary
- Phase 2 Seabreeze STAT COPD study initiated after FDA agreement on final protocol.
- Study evaluates single-dose rademikibart vs placebo as adjunct to standard of care for acute COPD exacerbations.
- Approximately 160 participants with type 2 inflammation (eosinophils ≥300 cells/μL) will be enrolled.
- Primary endpoint: treatment failure rate over 28 days; topline data expected in first half of 2026.
- Post-hoc analysis of prior Phase 2b asthma data in COPD-like patients to be presented at ATS 2025.

## SEC filing metadata
- accession: 0001835268-25-000029
- form_type: 8-K
- ticker: CNTB
- cik: 0001835268
- company_name: Connect Biopharma Holdings Ltd
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835268/000183526825000029/0001835268-25-000029-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835268/000183526825000029/cntb-20250514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001835268-25-000029
- JSON: https://secwatch.observer/filing/0001835268-25-000029.json
- Plain text: https://secwatch.observer/filing/0001835268-25-000029.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.